Metformin trial for brain tumor survivors’ brain and behavior
Part of Cancer, Mental health clinical trials.
This Phase 3 study tests whether metformin can improve brain function, behavior, and thinking in children and teens who were treated for certain brain tumors. You may be able to join if you meet age, time-since-treatment, language, and health/lab safety requirements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 7 years to 21 years (and 11 months) old when you enroll
- Be at least 3 weeks past the end of main brain-tumor treatment (or specific radiation timing for some tumors)
- Be able to take tablets (swallowed whole or crushed, or through a feeding tube) and be willing to follow the study schedule
- Have kidney and liver tests that fall in the “normal” ranges the study requires
- Be able to join the study in English (or French at some sites) or have had at least 2 years of schooling in that language
- Have no key conditions that the study excludes (examples: metformin allergy, certain diabetes, low IQ, major kidney problems)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether metformin, a common diabetes medicine, can help protect thinking and memory skills in people who have had radiation for a brain tumor. You will use a smartwatch and take online tests from home to track your progress.
This Phase 2 study tests whether adding metformin to the usual treatment for newly diagnosed glioblastoma (GBM) can improve outcomes. It involves taking metformin after surgery along with standard care (the Stupp protocol).
This Phase 2 study tests whether adding metformin to standard radiation and temozolomide (chemo) can improve outcomes for people with newly diagnosed glioblastoma of a specific metabolic subtype. It aims to see if this combination is safer and more effective than standard treatment alone.
This trial tests if adding metformin, a common diabetes drug, to standard chemotherapy or immunotherapy can help treat advanced solid tumors. It may be an option for people who are already eligible for chemo or immunotherapy.
This Phase 1 trial tests whether dapagliflozin (an SGLT2 medicine) can help shrink or control certain pediatric brain tumors or other solid tumors that have come back or won’t respond. It’s designed mainly to check safety and early signs of effect in children and young adults who have limited treatment options.
This trial tests if metformin can help treat a certain type of brain tumor called PFA ependymoma that has come back after surgery and radiation. It's for people ages 1 to 39 who are healthy enough for surgery or have tumors that can be measured on scans.
Hear when a new Medulloblastoma, Childhood trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.